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Infectious diseases are complex, dynamic, and constantly evolving. Examples during the past 15 years range from changes in transmission patterns of human monkeypox and dengue; more frequent re-emergence of cholera, legionnaire's disease, E. coli 0157, hepatitis C and, the haemorrhagic fevers -Marburg, Lassa and Ebola; and emergence of bovine spongiform encephalopathy (BSE), severe acute respiratory syndrome (SARS) and H5N1 influenza.
Causes of emergence and re-emergence include weakened public health infrastructure, increases in human and domestic animal populations, rapid urbanization, and effects on the environment from global warming to deforestation and flooding. Human behavior also plays a major role, ranging from unsafe sexual practices to over-or under-prescribing of antimicrobial drugs, patient adherence, unregulated sale, and indiscriminate use in humans, plants and animals.
Emerging and re-emerging infections occur in a world where international travel and trade facilitate their spread, and where their impact affects economies as well as health. Attempts at regulation to prevent their international spread occurred first in the 14th century quarantines in Venice. They continued during the 19th and 20th centuries in Europe and the Americas through a series of conferences and conventions leading to the International Health Regulations. The goal of the Regulations is to strengthen national capacities to detect and respond to emerging or re-emerging infections when and where they occur, with the guarantee of a safety net of collective detection and response should they cross international borders.
The lesson over the past 15 years -whether from the global response to SARS or preparations for the next influenza pandemic -is that collective action will decrease our vulnerability, and increase our public health security. The challenge is to ensure resources for our collective action under the framework of the International Health Regulations. University of Texas Medical Branch at Galveston, Galveston, TX, USA Background: Several studies have shown that watchful waiting management of acute otitis media (AOM) can be an alternative to immediate antibiotics. In practice, clinicians may be more comfortable using the watchful waiting option when the child has mild symptoms and the ear is not severely inflamed. Regarding clinical trials, standardized criteria for the diagnosis of AOM, and a clear description of TM findings has often been lacking, making interpretation of study results somewhat difficult. The objective of this paper will be to define AOM, review the development of an Ear Card methodology for assessing the child with AOM, and describe the effective use of the Ear Card in a clinical trial.
Methods: The Ear Card system for assessing the child with AOM was evaluated for concurrent correlation, sequence validity and reliability against previously published questionnaires. Responsiveness was assessed during a randomized clinical trial. Results: The system demonstrated excellent sequence validity, concurrent correlation and reliability.
Conclusions: The Ear Card combines a parent assessment of severity using a faces scale and the clinician's assessment of the tympanic membrane to provide an evaluation of total AOM severity that can be used to characterize AOM signs and symptoms at enrollment and to evaluate a patients progress during treatment. For research, clinical investigators can be reliably trained using the Ear Card, so that clinical characteristics at enrollment and follow-up can be clearly defined and scored. The method is sufficiently sensitive to detect small differences in outcomes between treatment groups. The Ear Card has also been useful in teaching residents and students to accurately assess the tympanic membrane.
Clinicians, AOM researchers, and clinical educators from around the world have requested our copyrighted electronic version of the Ear Card, which may be freely used for patient care, teaching and research. doi:10.1016/j.ijid.2008.05.139
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Summary of Studies With New Antibiotics in AOM in Last Decade -Where Are We?
A. Arguedas
Instituto de Atención Pediátrica, San Jose, Costa Rica
In the last decade multiple clinical antimicrobials with new antibiotics have been performed in children. During this time, the design of the clinical trial improved dramatically to take into consideration multiple factors but always keeping as the most critical factor the resolution of signs and symptoms from the participant children. In this regard, trial have taking into consideration the use of innovative
